Here To Stay: Inception Sciences Shows Why Build-To-Buy Works
This article was originally published in Start Up
Born at a time when venture capital found few exit opportunities for early-stage companies, build-to-buy helped mitigate the risk in investing in uncharted science. But the model is flourishing even in this period of wider capital options.
You may also be interested in...
ARCH invests $150m in the Scangos-led Vir Biotechnology; Flagship recruits ex-Novartis executive Epstein; Versant closes a new $400m fund; and $601.1m in 11 other recent VC funding rounds.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
Versant and Celgene have partnered again to launch a build-to-buy biotech, this time focusing on inflammatory bowel disease.